CAR T-Cell Neurotoxicity Detection Market in 2025 Sees 54.5% Share from B-cell Malignancies
Based on CAR T-cell neurotoxicity detection market forecasts, the growing demand for personalized medicines and technological advancements bolsters market growth. North America dominated the global market owing to favorable research infrastructure and government support.
CAR T-Cell Neurotoxicity Detection Market is evolving with innovations in diagnostics and clinical safety from 2024 to 2034.
North America is leading the CAR T-cell neurotoxicity detection market due to the presence of key players, favorable government support, and the rising prevalence of blood cancers.
The CAR T-cell neurotoxicity detection market includes 6 segments including by detection method, by product/service type, by biomarker source, by end-user, by indication, and by region.
Some key players include Thermo Fisher Scientific, GE Healthcare, and Neuropace, Inc.
Key trends include the growing research and development activities, increasing investments, and the rising demand for personalized medicines.
Some common types of blood cancers that can be treated using CAR T-cells are adult and pediatric B-cell precursor acute lymphoblastic leukemia, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and multiple myeloma.
Cytokine release syndrome (CRS), blood disorders, infections, and long-term side effects are other potential side effects of the CAR T-cell therapy.
Clinicaltrials.gov, Food and Drug Administration, Canadian Cancer Society, GOV.UK
Download Sample
Order Now
.webp){kind=small}
Report Description